Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Zhendong Chen"'
Autor:
Jie Fang, Zhendong Chen
Publikováno v:
Contrast Media & Molecular Imaging. 2022:1-8
The objective of this study was to investigate the value of PET/CT imaging based on CNN image registration algorithm in evaluating the short-term efficacy of PD-1 monoclonal antibody immunotherapy for lymphoma. 36 patients with advanced lymphoma conf
Autor:
Xiaoyan Chen, Guangze Li, Xingxing Diao, Zitao Guo, Mengling Liu, Jinghua Yu, Qi Huang, Jian Meng, Yaru Xue, Dafang Zhong, Yuandong Zheng, Zhendong Chen, Yali Wu
Publikováno v:
Drug Metabolism and Disposition. 50:809-818
Excretion of [14C]HR011303-derived radioactivity showed significant species difference. Urine (81.50% of dose) was the main excretion route in healthy male subjects, whereas feces (87.16% of dose) was the main excretion route in rats. To further eluc
Autor:
Xiaojing Zhang, Zhiqiang Meng, Shanzhi Gu, Shukui Qin, Zhendong Chen, Xiao Zhang, Linna Wang, Xinni Chen, Jianjun Zou, Ying Liu, Jianping Xiong, Zhenggang Ren
Publikováno v:
International Journal of Cancer. 149:1944-1954
Biliary tract cancer (BTC) is a highly malignant tumor with limited treatment options and poor prognosis. Our study aimed to evaluate camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced BTC. In this multicenter, open-l
Publikováno v:
Current Drug Metabolism. 22:838-857
Metabolite identification plays a critical role in the phases during drug development. Drug metabolites can contribute to efficacy, toxicity, and drug-drug interaction. Thus, the correct identification of metabolites is essential to understand the be
Autor:
Jian-jun Zou, Yifan Zhang, Dafang Zhong, Xiao-fei Chen, Xin liang, Y. L. Zhu, Yan-mei Liu, Qian Chen, Hai-yan Liu, Jingying Jia, Zhendong Chen, Chen Yu, Yan Zhan
Publikováno v:
Clinical Therapeutics. 43:e264-e273
Purpose Henagliflozin is a highly selective and effective sodium glucose co-transporter (SGLT)-2 inhibitor developed for the treatment of patients with type 2 diabetes mellitus (T2DM). This study aimed to investigate the effects of meal intake on the
Publikováno v:
European journal of clinical pharmacology. 78(12)
A population pharmacokinetic (PPK) model for creatinine was successfully developed using creatinine concentration data from 6 healthy male volunteers with and without ingestion of 225 g boiled beef as an exogenous creatinine source. A model with firs
Autor:
Guisheng Li, Qiong Wu, Jin Li, Xiuwen Wang, Yiye Wan, Ying Cheng, Jianping Xiong, Chunhong Hu, Jianqiang Cai, Yong-Qiang Li, Yong Tang, Helong Zhang, Jiang liu, Baoli Qin, Jifeng Feng, Jian Dong, Jianfeng Zhou, Yongqian Shu, Xingwen Li, Jianhong Wang, Yongkun Sun, Minhui Wu, Yigui Chen, Nong Xu, Zhendong Chen, Yuxian Bai, Jufeng Wang, Yanhong Deng, Da Jiang, Yi Ba, Chengxue Dang, Yujuan Qi, Jianming Xu, Donglin Wang, Yihebali Chi
Publikováno v:
Oncologist
Background Treatment options for refractory metastatic colorectal cancer (mCRC) were limited. Anlotinib is a novel multitarget tyrosine kinase inhibitor. ALTER0703 study was conducted to assess efficacy and safety of anlotinib for patients with refra
Publikováno v:
Mathematical Biosciences and Engineering, Vol 18, Iss 4, Pp 4477-4490 (2021)
The precise radiotherapy of esophageal cancer may cause different degrees of radiation damage for lung tissues and cause radioactive pneumonia. However, the occurrence of radioactive pneumonia is related to many factors. To further clarify the correl
Autor:
Hua Zhang, Yifan Zhang, Xiao-yun Liu, Jing-Jing Bao, Liyan Miao, Zhendong Chen, Yong Jiang, Dafang Zhong, Jian Meng
Publikováno v:
Acta Pharmacol Sin
Furmonertinib was designed for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. In this study, we investigated the metabolic disposition and mass balance in humans and tissue distribution in rats. After a single
Autor:
Zhendong Chen, Hongbing Wang, Shukui Qin, Peiguo Cao, Weiguo Su, Sanyuan Sun, Haihui Chen, Jian Li, Jianfeng Zhou, Haijun Zhong, Yanhong Deng, Rubing Han, Lei Yang, Shubin Wang, Weijian Guo, Donghui Chen, Dong Ma, Xiaojun Guo, Rui-Hua Xu, Wei Li, Zhuang Yu, Ying Cheng, Tianshu Liu, Jin Li, Yongqian Shu, Bin Zhang, Jiejun Wang, Hongming Pan, Jianming Xu, Yuxian Bai, Ning Wang, Nong Xu, Changping Wu, Ying Yuan
Publikováno v:
Future Oncology. 17:1339-1350
Background: FRESCO study demonstrated efficacy and safety of fruquintinib in metastatic colorectal cancer patients. Impact of prior targeted therapy (PTT) on efficacy and safety of fruquintinib was evaluated. Materials & methods: In this subgroup ana